hrp0092p1-226 | Growth and Syndromes (to include Turner Syndrome) (1) | ESPE2019

Response to Growth Hormone in Very Young Children (® International Outcome Study and ANSWER Program

Rohrer Tilman R , Miller Bradley , Ostrow Vlady , Pietropoli Alberto , Polak Michel , Ross Judith

Objectives: Limited information is available on how very young children with growth hormone deficiency (GHD) respond to growth hormone (GH) replacement. We compared response to 1 year of GH therapy in children aged <2 years and prepubertal children aged ≥2 years.Methods: The two non-interventional, multicentre studies, NordiNet® International Outcome Study (IOS) (NCT00960128) and the ANSWER Prog...

hrp0092p1-299 | Adrenals and HPA Axis (2) | ESPE2019

Medical Identification Jewellery Use in Children and Young Adults with Adrenal Insufficiency

Chrisp Georgina , Falhammar Henrik , Quartararo Maria , Torpy David , Rushworth R. Louise

Background: Adrenal insufficiency (AI) is a rare disorder in the paediatric population. Patients are at risk of an adrenal crisis (AC), which comprises hypotension, acute abdominal symptoms, reduced consciousness, hypoglycaemia, hyperkalaemia and hyponatremia. Immediate administration of parenteral hydrocortisone is essential to prevent AC progression but delays may occur when health attendants are unaware of the underlying AI diagnosis. Medical jewellery is a...

hrp0092p2-268 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

The Effect of Vitamin D Supplementation on Androgen Levels of Adolescent Girls with Hyperandrogenism

Çig Esranur , Atar Müge , Pirgon Özgür

Aim: The aim of this study was to evaluate the effect of different doses of vitamin D supplementation on androgen levels in adolescent girls who were treated with metformin.Method: 45 adolescent girls diagnosed with hyperandrogenism were divided into the 3 different groups according to the treatment scheme. Patients treated with metformin (850 mg / day oral)(n = 15), metformin and vitamin D drops (2,000 IU / day)(<em...

hrp0089fc14.5 | Multisystem Endocrine Disorders | ESPE2018

Pubertal Females Produce an Enhanced Interferon-Alpha, Anti-viral Response Compared to Males, Which is Associated with X Chromosome Number, and Not Sex Hormones

Webb Kate , Butler Gary , Ciurtin Coziana , Peckham Hannah , Radziszewska Anna , Wedderburn Lucy R , Ioannou John

Introduction: Very little is known about the development of the immune system during puberty. Autoimmune diseases, like juvenile onset systemic lupus erythematosus (jSLE), have an unexplained female bias and a higher incidence after puberty. IFN alpha (IFNα) is a potent antiviral cytokine, and jSLE has a strong IFNα transcriptional signature. Toll like receptors 7 and 9 (TLR7/9) sense viral RNA and DNA respectively, and trigger plasmacytoid dendritic cells (pDC) to p...

hrp0089fc14.6 | Multisystem Endocrine Disorders | ESPE2018

Sex Differences in Autoimmune Disease: Testosterone is Associated with a Decrease in Expression of Key Anti-viral Genes During Puberty, Which may Decrease the Risk of Autoimmunity in Males

Webb Kate , Butler Gary , Ciurtin Coziana , Peckham Hannah , Radziszewska Anna , Wedderburn Lucy R , Ioannou Yiannis

Introduction: There are well described sex differences in the immune system. It has been shown in both innate and adaptive immunity that females have a more robust response than males. Various autoimmune diseases have a strong sex bias towards females. It is the accepted dogma that oestrogen in females relates to an increased risk of autoimmunity, but evidence to this end is scarce. Interferon alpha (IFNα) is a potent anti-viral innate cytokine, and many autoimmune diseas...

hrp0089p1-p163 | Growth &amp; Syndromes P1 | ESPE2018

The Association between Growth Hormone Dose and Short-Term Height Outcomes in a Large Cohort of Paediatric Patients with Turner Syndrome: Real-World Data from the NordiNet® International Outcome Study (IOS) and ANSWER Program

Blair Jo , Rohrer Tilman R. , Tonnes Pedersen Birgitte , Roehrich Sebastian , Backeljauw Philippe

Objectives: The recently updated clinical practice guidelines for Turner syndrome (TS) recommend a growth hormone (GH) dose of 45–50 μg/kg/day, increasing to 68 μg/kg/day in case adult height potential is substantially compromised (1). Real-world data on the modifiable factors impacting near-adult height in GH-treated TS patients are limited, but short-term responsiveness to GH has been suggested as one factor (2). We, therefore, analysed the impact of GH dose o...

hrp0089p2-p252 | Growth &amp; Syndromes P2 | ESPE2018

Final Results of NordiNet® International Outcome Study: Key Outcomes in Paediatric Patients

Polak Michel , Blair Jo , Rohrer Tilman R. , Pietropoli Alberto , Tonnes Pedersen Birgitte , Savendahl Lars

Background: NordiNet® International Outcome Study ([IOS]; NCT00960128), a non-interventional study (2006–2016), assessed the effectiveness and safety of real-world treatment with Norditropin®. Outcomes were assessed in children with growth hormone deficiency (GHD), born small for gestational age (SGA), Turner syndrome (TS), chronic renal disease (CRD), idiopathic short stature (ISS), Noonan syndrome (NS) and Prader-Willi syndrome (PWS)....

hrp0086p1-p616 | Growth P1 | ESPE2016

Serum IGF-I, IGFBP-3 and Als Concentrations and Physical Performance in Young Swimers During a Training Season

Filho Hugo Tourinho , Pires Marcela , Puggia E F , Papoti M , Barbieri R , Martinelli Jr Carlos

Background: Exercise programs are related to the anabolic function of GH/IGF-I axis.Objective and hypotheses: To analyse IGF-I, IGFBP-3 and ALS serum concentrations in adolescent swimmers at different stages of training season, and compare them with physical performance and body composition.Method: Nine male athletes, aged 16–19 years, who trained regularly throughout the season, were studied. IGF-I, IGFBP-3 and ALS were recor...

hrp0086p2-p643 | Growth P2 | ESPE2016

An Analysis of the Safety of Childhood Growth Hormone (GH) Therapy: Data from the NordiNet® International Outcome Study (IOS)

Savendahl Lars , Rohrer Tilman R , Pournara Effie , Pedersen Birgitte Tonnes , Blankenstein Oliver

Background: NordiNet® IOS (NCT00960128), a non-interventional study, collects long-term effectiveness and safety data of GH (Norditropin®, Novo Nordisk) treatment in everyday clinical practice.Objective and hypotheses: Identify paediatric patients more likely to experience a second adverse event (AE).Method: Based on diagnosis at GH treatment start and associated risk for mortality, patients were cla...

hrp0082fc8.6 | Fat Metabolism | ESPE2014

A Novel Missense Variant in the Insulin Receptor Gene in Three Unrelated Irish Families with Severe Insulin Resistance Syndrome: Evidence for an Irish Founder Effect

Mavinkurve M , O'Connell S , Cody D , Isaac I , Harris J , Semple R K , Mc Donnell C

Background: Genetic defects in the insulin receptor (INSR) are rare. Precise prevalence is unknown and significant clinical heterogeneity exists. Over 120 allelic variants have been described to date, spread throughout the receptor, and few geographical founder effects have been described. In this case series we identify a novel missense mutation in the tyrosine kinase domain of the INSR in three independently ascertained Irish families.Objective and Hyp...